NuPathe Inc (fka PATH) (PATH)

[lovethatgreen]

NuPathe’s transformative SmartRelief technology positions the company to capitalize on the
rapidly expanding global transdermal market (forecasted to increase from $21.5 to $31.5 billion by
2015), by potentially opening entirely new classes of medications for delivery through the skin.

"Here are some rough estimates from NuPathe's own presentation.

Annual gross revenue per patient using 2 patches/month average price of $90/patch

$80/patch = $1,900
$90/patch = $2,160
$100/patch = $2,400

lets say NuPathe captures 10% of the 12.5 million estimated patient opportunities. That is 1.25 million x median price $2,160/year = $2.7 Billion/year in sales.

NuPathe has 14,748,582 outstanding shares which translates to $183 revenue per share. That is CRAZY.